Safety Implications of Modulating Nuclear Receptors: A Comprehensive Analysis from Non-Clinical and Clinical Perspectives

被引:0
|
作者
Rao, Mohan [1 ]
Mcduffie, Eric [1 ]
Srivastava, Sanjay [2 ]
Plaisted, Warren [3 ]
Sachs, Clifford [1 ]
机构
[1] Neurocrine Biosci Inc, Toxicol Dept, San Diego, CA 92130 USA
[2] Neurocrine Biosci Inc, Chem Dept, San Diego, CA 92130 USA
[3] Neurocrine Biosci Inc, Biol Dept, San Diego, CA 92130 USA
关键词
toxicoinformatics; big data analytics; nuclear receptor modulation; gene expression analysis; off-target interactions; PROLIFERATOR-ACTIVATED RECEPTORS; PPAR-GAMMA; DRUG DISCOVERY; GLITAZONES; ATTRITION; TOXICITY; GENE; IDENTIFICATION; METABOLITES; MECHANISMS;
D O I
10.3390/ph17070875
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The unintended modulation of nuclear receptor (NR) activity by drugs can lead to toxicities amongst the endocrine, gastrointestinal, hepatic cardiovascular, and central nervous systems. While secondary pharmacology screening assays include NRs, safety risks due to unintended interactions of small molecule drugs with NRs remain poorly understood. To identify potential nonclinical and clinical safety effects resulting from functional interactions with 44 of the 48 human-expressed NRs, we conducted a systematic narrative review of the scientific literature, tissue expression data, and used curated databases (OFF-X (TM)) (Off-X, Clarivate) to organize reported toxicities linked to the functional modulation of NRs in a tabular and machine-readable format. The top five NRs associated with the highest number of safety alerts from peer-reviewed journals, regulatory agency communications, congresses/conferences, clinical trial registries, and company communications were the Glucocorticoid Receptor (GR, 18,328), Androgen Receptor (AR, 18,219), Estrogen Receptor (ER, 12,028), Retinoic acid receptors (RAR, 10,450), and Pregnane X receptor (PXR, 8044). Toxicities associated with NR modulation include hepatotoxicity, cardiotoxicity, endocrine disruption, carcinogenicity, metabolic disorders, and neurotoxicity. These toxicities often arise from the dysregulation of receptors like Peroxisome proliferator-activated receptors (PPAR alpha, PPAR gamma), the ER, PXR, AR, and GR. This dysregulation leads to various health issues, including liver enlargement, hepatocellular carcinoma, heart-related problems, hormonal imbalances, tumor growth, metabolic syndromes, and brain function impairment. Gene expression analysis using heatmaps for human and rat tissues complemented the functional modulation of NRs associated with the reported toxicities. Interestingly, certain NRs showed ubiquitous expression in tissues not previously linked to toxicities, suggesting the potential utilization of organ-specific NR interactions for therapeutic purposes.
引用
收藏
页数:22
相关论文
共 50 条
  • [1] Oligonucleotide-based pharmaceuticals: Non-clinical and clinical safety signals and non-clinical testing strategies
    Mustonen, Enni-Kaisa
    Palomaki, Tiina
    Pasanen, Markku
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2017, 90 : 328 - 341
  • [2] Clinical and non-clinical safety of artemisinin derivatives in pregnancy
    Gomes, Caroline
    Boareto, Ana Claudia
    Dalsenter, Paulo Roberto
    [J]. REPRODUCTIVE TOXICOLOGY, 2016, 65 : 194 - 203
  • [3] Non-clinical vaccine safety assessment
    Verdier, F
    [J]. TOXICOLOGY, 2002, 174 (01) : 37 - 43
  • [4] CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion
    Wallis, Rob
    Benson, Charles
    Darpo, Borje
    Gintant, Gary
    Kanda, Yasunari
    Prasad, Krishna
    Strauss, David G.
    Valentin, Jean-Pierre
    [J]. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2018, 93 : 15 - 25
  • [5] Exploratory clinical trials: A non-clinical drug safety perspective
    Weaver, R. J.
    [J]. TOXICOLOGY LETTERS, 2011, 205 : S2 - S2
  • [6] Non-clinical reporting of nuclear cardiology imaging
    Nortje, J.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S393 - S393
  • [7] Non-Clinical Safety of Ciliary Muscle Electrotransfection
    Bordet, Thierry
    Bigot, Karine
    Benard, Romain
    Laffitte, Jean-Denis
    Touchard, Elodie
    Buggage, Ronald
    Behar-Cohen, Francine F.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [8] Cardiac safety of lacosamide: the non-clinical perspective
    Delaunois, A.
    Colomar, A.
    Depelchin, B. O.
    Cornet, M.
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2015, 132 (05): : 337 - 345
  • [9] Perspectives on non-clinical safety evaluation of drug metabolites through the JS']JSOT workshop
    Minagawa, Toshiya
    Nakano, Kenji
    Furuta, Shigeru
    Iwasa, Takashi
    Takekawa, Koji
    Minato, Kouichi
    Koga, Toshihisa
    Sato, Takashi
    Kawashima, Kosuke
    Kurahashi, Yoshikazu
    Onodera, Hiroshi
    Naito, Shinsaku
    Nakamura, Kazuichi
    [J]. JOURNAL OF TOXICOLOGICAL SCIENCES, 2012, 37 (04): : 667 - 673
  • [10] Thromboelastographic phenotypes of fibrinogen and its variants: Clinical and non-clinical implications
    Galanakis, Dennis K.
    Neerman-Arbez, Marguerite
    Brennan, Stephen
    Rafailovich, Miriam
    Hyder, Luke
    Travlou, Oreanthi
    Papadakis, Emmanuel
    Manco-Johnson, Marilyn J.
    Henschen, Agnes
    Scharrer, Inge
    [J]. THROMBOSIS RESEARCH, 2014, 133 (06) : 1115 - 1123